Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
269.20
-8.60 (-3.10%)
At close: Apr 28, 2026
Market Cap 23.93B
Revenue (ttm) 182.97M
Net Income (ttm) -74.71M
Shares Out 88.88M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 148,992
Average Volume 425,218
Open 277.80
Previous Close 277.80
Day's Range 262.80 - 277.80
52-Week Range 178.00 - 314.80
Beta n/a
RSI 61.44
Earnings Date Jun 18, 2026

About HKG:2526

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company’s products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2016
Employees 182
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2526
Full Company Profile

Financial Performance

In 2025, HKG:2526's revenue was 164.42 million, an increase of 133.72% compared to the previous year's 70.35 million. Losses were -67.14 million, 54.8% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.